Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $29.7 million.

  • Viking Therapeutics' Share-based Compensation fell 18.33% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year increase of 34.75%. This contributed to the annual value of $29.7 million for FY2024, which is 77.39% up from last year.
  • Latest data reveals that Viking Therapeutics reported Share-based Compensation of $29.7 million as of FY2024, which was up 77.39% from $16.8 million recorded in FY2023.
  • Viking Therapeutics' 5-year Share-based Compensation high stood at $29.7 million for FY2024, and its period low was $5.8 million during FY2020.
  • In the last 3 years, Viking Therapeutics' Share-based Compensation had a median value of $16.8 million in 2023 and averaged $18.4 million.
  • Data for Viking Therapeutics' Share-based Compensation shows a peak YoY soared of 93.13% (in 2023) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Share-based Compensation (Yearly) stood at $5.8 million in 2020, then grew by 4.85% to $6.1 million in 2021, then skyrocketed by 42.18% to $8.7 million in 2022, then soared by 93.13% to $16.8 million in 2023, then surged by 77.39% to $29.7 million in 2024.